 BOSTON, Jan. 4, 2022 PRNewswire -- Stealth BioTherapeutics Corp Nasdaq: MITO, a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at the H.C. Wainwright BioConnect Virtual Conference taking place from January 10-13, 2022. 